Revelation Biosciences Updates on $14.1M Cash & Q4 2026 Start for Pivotal AKI Trial
REVB sits 25% above its 52-week low of $0.875.
Summary
Revelation Biosciences released an updated corporate presentation, confirming $14.1 million in cash to fund operations into Q1 2027 and announcing the planned Q4 2026 start for its pivotal Phase 2/3 AKI clinical trial.
Key Events · Product Development and Regulatory · REVB
-
Cash Runway Confirmed
The company reports $14.1 million in cash, sufficient to fund operations into Q1 2027, addressing prior "going concern" warnings and providing crucial financial stability.
-
Pivotal AKI Trial Timeline Set
The Phase 2/3 TITAN study for Gemini in Acute Kidney Injury (AKI), a significant market with no approved treatments, is estimated to begin in Q4 2026.
-
Lead Program Progress Highlighted
The presentation details positive preclinical and Phase 1 clinical data for Gemini, supporting its mechanism of action and potential in reducing inflammation and fibrosis.
Analysis · REVB · Life Sciences
This 8-K provides an updated corporate presentation confirming Revelation Biosciences has $14.1 million in cash, extending its runway into Q1 2027. This financial stability is critical for a company that recently issued a "going concern" warning. The presentation also details plans to initiate the pivotal Phase 2/3 TITAN study for its lead drug candidate, Gemini, in Acute Kidney Injury (AKI) in Q4 2026, outlining a clear path forward for its key program.
At the time of this filing, REVB was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.88 to $13.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.